Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells

Archive ouverte

Leclerc, Justine | Garandeau, David | Pandiani, Charlotte | Gaudel, Céline | Bille, Karine | Nottet, Nicolas | Garcia, Virginie | Colosetti, Pascal | Pagnotta, Sophie | Bahadoran, Philippe | Tondeur, Garance | Mograbi, Baharia | Dalle, Stéphane | Caramel, Julie | Levade, Thierry | Ballotti, Robert | Andrieu-Abadie, Nathalie | Bertolotto, Corine

Edité par CCSD ; Nature Publishing Group [1987-....] -

International audience. Phenotypic plasticity and subsequent generation of intratumoral heterogeneity underly key traits in malignant melanoma such as drug resistance and metastasis. Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator. Here, we show that the acid ceramidase ASAH1, which controls sphingolipid metabolism, acted as a rheostat of the phenotypic switch in melanoma cells. Low ASAH1 expression was associated with an invasive behavior mediated by activation of the integrin alphavbeta5-FAK signaling cascade. In line with that, human melanoma biopsies revealed heterogeneous staining of ASAH1 and low ASAH1 expression at the melanoma invasive front. We also identified ASAH1 as a new target of MITF, thereby involving MITF in the regulation of sphingolipid metabolism. Together, our findings provide new cues to the mechanisms underlying the phenotypic plasticity of melanoma cells and identify new anti-metastatic targets.

Suggestions

Du même auteur

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

Archive ouverte | Garandeau, David | CCSD

International audience. BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) re...

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

Archive ouverte | Garandeau, David | CCSD

International audience. Abstract BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate...

REGULATION OF MELANOGENESIS BY THE AMINO-ACID TRANSPORTER SLC7A5.

Archive ouverte | Gaudel, Céline | CCSD

International audience. Integration of ChIPseq and microarray data allowed to identify to our knowledge previously unreported MITF target genes, among which, the amino acid transporter, SLC7A5. We showed that siRNA-...

Chargement des enrichissements...